Navigation Links
BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality

istered via the coronary artery, as a liquid that is injected during catheterization into the damaged heart muscle. The liquid polymerizes within the tissue and forms a protective scaffold that enhances the mechanical strength of the heart muscle during recovery and repair thereby preventing pathological enlargement of the left ventricle after the heart attack. BL-1040 degrades naturally six weeks after injection.

Patients who have undergone an acute MI (AMI) with severe heart damage are the most likely to benefit from BL-1040. Approximately 40% of AMI patients develop left ventricle dilatation or heart failure, which carries a substantially greater mortality risk. This population includes approximately 380,000 patients in the U.S., with a total estimated U.S. market of over $1.5 billion.

BL-1040 was in-licensed from Ben-Gurion University through its business company BGN Technologies, and was developed by Professor Smadar Cohen and Professor Jonathan Leor from the Department of Biotech and Biomedical Engineering at Ben-Gurion University.

About BioLineRx

BioLineRx, a clinical stage drug development company traded on the Tel Aviv Stock Exchange (BLRX), is dedicated to building a robust pipeline of promising therapeutics for unmet medical needs. The Company's current product pipeline consists of 10 compounds, 3 of which are in or impending clinical trials. Its lead product, BL-1020, for the treatment of schizophrenia, successfully completed Phase 1 clinical trials; and BL-1040, for the treatment of damaged heart tissue post myocardial infarction, is expected to enter the clinic in the second quarter of 2007. Additional products under development include compounds for the treatment of cancer and CNS, cardiovascular, metabolic, infectious and autoimmune diseases.

BioLineRx advances projects from early stage discovery and lead generation to advanced clinical trials, regulatory approval and marketing. Partnering with researchers, universi
'"/>




Page: 1 2 3

Related medicine technology :

1. BioLineRx Presents Data From Successful Phase I Trial for BL-1020 in Schizophrenia at American Psychiatric Association Conference
2. BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming Clinical Conferences
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:7/27/2015)... , July 27, 2015 According ... Hybridization Market Study (2014-2019) by Type (DNA ISH, RNA ... By End User (Hospitals, Pharma & Biotech Companies, Research ... at $554.4 million 2014 and is estimated to reach ... during the forecast period, 2014 to 2019. ...
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/v4wlnk/key_pharma_news ) ... Pharma News Issue" newsletter to their offering. ... burgeoning oncology pipeline and serves as a statement ... in 2015, with a large-scale potentially transformative acquisition ... Key Pharma News covers all major developments in ...
(Date:7/27/2015)... -- Cardica, Inc. (Nasdaq: CRDC ) today announced that it ... June 30, 2015, on Thursday, August 6, 2015, after the ... 4:30 p.m. Eastern Time to discuss the financial results and ... Conference Call Details To access the live conference call on ... please dial 877-703-6106 from the United States ...
Breaking Medicine Technology:Global In-Situ Hybridization Market to be Worth $681.0 Million by 2019 2Global In-Situ Hybridization Market to be Worth $681.0 Million by 2019 3Key Pharma News Issue - Gilead will make further oncology deals in 2015 2Key Pharma News Issue - Gilead will make further oncology deals in 2015 3Cardica To Announce Fiscal 2015 Fourth Quarter Financial Results On Thursday, August 6, 2015 2
... , WALTHAM, Mass., Dec. 14 According ... technology market intelligence, increased use of safety devices for small-bore ... driver of the enteral feeding device markets in both the ... for Enteral Feeding Devices 2010 report finds that the ...
... Colo., Dec. 14 Manchester Pharmaceuticals, Inc.(TM) announced today ... On October 22, 2009, the US Food and Drug ... suffering from gallstones in whom surgery poses an unacceptable ... Chenodal prescriptions have started to be dispensed to patients ...
Cached Medicine Technology:Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3Manchester Announces Availability of Chenodal(TM) 2
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... The heroin ... country, reported WCNC on July 7th. The rate for heroin usage has ... has gone down considerably, and is a less expensive alternative for those with an ...
(Date:7/27/2015)... ... July 27, 2015 , ... In a piece ... personal side of plastic surgery and explained why people should not shy away from ... for the excesses of the few and celebrate it for the modern wonder that ...
(Date:7/27/2015)... Plains, NJ (PRWEB) , ... July 27, 2015 , ... ... tendon of an accomplished athlete. “The patient is high-end athlete, whose accomplishments include ... after 8 months of Achilles tendon pain, which was diagnosed as tendinitis. I ...
(Date:7/27/2015)... , ... July 27, 2015 , ... ... including emergency notification and mobile collaboration, announced today the ... user interface, language localization and other feature enhancements. , This software release gives ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... and in-depth research report. The report provides basic information such as calcium ... This report covers the global (US, Europe, Japan etc) industry analysis like ...
Breaking Medicine News(10 mins):Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 3Health News:Recent Op-Ed Defending Plastic Surgery Highlights the Personal Side of Cosmetic Procedures, says Beverly Hills Physicians 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 3Health News:Send Word Now Announces Release of New User Interface for its Award-Winning Mass Notification Service 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 3
... understanding of dopamine release from nerve cells, findings that ... treating Parkinson,s Disease. People with Parkinson,s Disease ... movement and, in extreme cases, a loss of physical ... of dopamine producing nerve cells in the brain. ...
... finds increase lowers chance of hospitalization or death ... with heart failure, high doses of the drug losartan, ... admission and death, a new study shows. , Though ... the study focused on whether dose level makes a ...
... ... expertise offers a winning combination to companies with large sales forces. , ... Chicago, IL (PRWEB) November 18, ... , knowledge and collaboration platform, and ELA Consulting Group , sales effectiveness and ...
... ... of resources to help community health officials make use of the company’s new mapping ... white paper and a free webinar, each demonstrate how Depiction can be used as ... ...
... A ... a new technique available at Houston weight loss surgery practice Texas Laparoscopic ... surgical treatment for morbid obesity. , ... (Vocus) November 18, 2009 -- Houston-based Texas Laparoscopic Consultants is a ...
... ... families learn five steps for creating joyful holidays and family celebrations. , ... (PRWEB) November 18, 2009 -- PAIRS Foundation is ... joyful holidays and family celebrations. , ,"Holidays can be a time of wonderful celebration, sharing ...
Cached Medicine News:Health News:Findings that should speed the development of drugs for Parkinson's disease 2Health News:Heart Failure Drug May Help More in Higher Doses 2Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 2Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 3Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 4Health News:Community Health Officials Can Improve Real Time H1N1 Information Sharing with New Resources from Depiction, Inc. 2Health News:Community Health Officials Can Improve Real Time H1N1 Information Sharing with New Resources from Depiction, Inc. 3Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 2Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 3Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 4Health News:Five Steps to Happy Family Gatherings at Holiday Time 2
The Nervous System Flash Cards product uses the time tested content and images from BryanEdwards.com and displays the necessary images to demonstrate the nervous system....
... Cochrane Reviews enable all those involved ... date with the very latest evidence in ... which becomes harder each year as the ... this problem by delivering the best single ...
... Cochrane Reviews enable all those involved ... date with the very latest evidence in ... which becomes harder each year as the ... this problem by delivering the best single ...
Pocket Medicine's Cardiology Bundle includes the following 4 applications: Treatment Strategies in Cardiovascular Medicine, Treatment Strategies in Interventional Cardiology, Treatment Strategies in ...
Medicine Products: